Management Team

Our management team is comprised of experienced executives with long track records of success in the development of pharmaceuticals, biotechnology drugs and medical devices.

David Hung, M.D.

Founder, President and Chief Executive Officer

Dr. Hung founded Nuvation Bio in 2018 and serves as President and Chief Executive Officer and member of the Board of Directors.

Dr. Hung founded Medivation, Inc., in 2003, raising a total of $433 million in public offerings over the life of the company to reach a market cap of more than $14 billion, providing investors with a return on investment of 21,000%. In 2016, Medivation was sold to Pfizer for $14.3 billion in an all-cash deal, one of the largest biopharma sales ever by a founding Chief Executive Officer. For his role in creating Medivation, Dr. Hung was named the Life Sciences category winner and Overall U.S. winner across all categories of the 2014 Ernst & Young Entrepreneur of the Year Award.

Dr. Hung identified, in-licensed and led bench-to-bedside development of enzalutamide (XTANDI®) for advanced prostate cancer. At Medivation, XTANDI was taken from first in vitro laboratory experiment to FDA approval in seven years, one of the fastest development timelines in pharmaceutical history. XTANDI, approved in 60+ countries, reached blockbuster drug status, reaching nearly $6 billion in global annual sales in 2023.

At Medivation, Dr. Hung identified, in-licensed and developed talazoparib, a potentially best-in-class PARP inhibitor, which was approved by the FDA in October 2018, and the immune-oncology agent, pidilizumab, which demonstrated robust effects in Phase 2 studies and is now a promising Phase 3-ready asset.

Between Medivation and founding Nuvation Bio, Dr. Hung served for 10 months as Chief Executive Officer at Axovant Sciences before tendering his resignation. Prior to founding Medivation, he served as President and Chief Executive Officer of ProDuct Health, Inc., a venture-backed startup medical device company founded in 1998 that developed, manufactured and commercialized a breast microcatheter – that he invented – for breast cancer risk assessment. ProDuct Health was acquired in 2001 for $168 million by Cytyc Corporation. Dr. Hung currently serves as Chairman of the Board of Directors of T-Therapeutics and as a member of the Board of Directors of Novocure.

Dr. Hung received an A.B. summa cum laude in biology from Harvard College and an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine. He completed simultaneous clinical fellowships in hematology, oncology and transfusion medicine as well as two basic science research fellowships in molecular biology at the University of California, San Francisco, School of Medicine.

David Hanley, Ph.D.

Chief Technical Operations Officer

Dr. Hanley joined Nuvation Bio in 2021, bringing 20 years of pharmaceutical industry experience driving strategy for technical operations and chemistry manufacturing and controls (CMC), including virtual networks, for drug development, manufacturing and distribution in the U.S. and worldwide. He holds diverse disease expertise, including oncology, central nervous system (CNS) and autoimmune, and product types, including biologics, small molecule therapies, cell therapies and synthetic peptide products.

Dr. Hanley most recently served as Senior Vice President and Head of Global Pharmaceutical Development and Operations at BioXcel Therapeutics, where he led strategy and execution for CMC development, end-to-end supply chain and external supply manufacturing. Prior, Dr. Hanley held positions at Radius Health, Inc., including Vice President of Pharmaceutical Sciences and Technical Operations. There, he led the end-to-end supply chain, including for CMC development, a U.S. Food and Drug Administration (FDA) New Drug Application (NDA) and FDA-approved product launch.  Dr. Hanley also held leadership positions at The Medicines Company, including Senior Director of Global Pharmaceutical Development, and project management and scientific positions at Medarex and Berlex, a subsidiary of Schering AG, at the start of his career.

Dr. Hanley earned his Ph.D. in Physical and Analytical Chemistry from the University of Utah and his B.S. in Chemistry from Virginia Commonwealth University.

Gary Hattersley, Ph.D.

Chief Scientific Officer

Dr. Hattersley joined Nuvation Bio in 2019 following a 15-year career at Radius Health Inc, where he supported the development of its oncology and women’s health portfolio, including TYMLOS®, approved by the FDA in 2017 for the treatment of postmenopausal women with osteoporosis at high risk of fracture. At Radius Health, Dr. Hattersley held roles of increasing seniority, including Chief Scientific Officer, Senior Vice President of Preclinical Development, and Vice President of Biology. Prior to Radius Health, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals, where he had responsibility for the discovery and development of novel small molecule agents for the treatment of metabolic bone diseases. He also held positions at Genetics Institute investigating the application of the bone morphogenetic proteins in musculoskeletal disease. Dr. Hattersley received a Ph.D. from St. George’s Hospital Medical School in London.

David Liu, M.D., Ph.D.

Chief Medical Officer

Dr. Liu joined Nuvation Bio in 2022 with over 20 years of experience leading the discovery and development of oncology therapies, including NDA submissions for multiple oncology assets in the U.S., Europe, and China. Most recently, Dr. Liu served as the Chief Medical Officer at a biotechnology company based in Shanghai, China. There, he built and led their clinical R&D organization, including global clinical research, global clinical operations, pharmacovigilance, biostatistics, programming and data management, clinical pharmacology, and drug supply.

Earlier in his career, Dr. Liu held several roles of increasing strategic responsibility at Bristol Myers Squibb, where he became a leader in Oncology Global Clinical Research, including leading the Global Prostate Cancer Program, Pediatric Clinical Development, and Translational Research for ipilimumab, and development of nivolumab and ipilimumab for China. After Bristol Myers Squibb, Dr. Liu was the Global Lead Physician at Celgene for the revlimid plus rituximab submission program in indolent lymphoma. Dr. Liu earned a Ph.D. from the Massachusetts Institute of Technology, an M.S. from the University of Toledo, and an M.D. from Beijing Medical University (Peking University School of Medicine). 

Stacy Markel

Chief People Officer

Ms. Markel joined Nuvation Bio in 2019. Previously, she served as Executive Vice President, Human Resources, at Rigel Pharmaceuticals, working collaboratively with the CEO and Executive Committee to support the successful evolution of the company from R&D to commercial stage. Prior to that role, Ms. Markel served as Senior Vice President of Human Resources at Portola Pharmaceuticals, Inc., where she helped successfully transition the company from a development-stage company to a commercial-stage company, preparing the organization for the launch of its first marketed product. Prior to Portola, Ms. Markel served as Senior Vice President of Human Resources and Professional Development at Actelion Pharmaceuticals, Ltd., where she was a member of the Executive Leadership Team and Global Human Resources Leadership Team. She was instrumental in the growth of the organization and in positioning culture as a key advantage in attracting and retaining talent. Ms. Markel has over 25 years of business experience in the pharmaceutical/biotechnology industry. She began her career in sales and sales management with Roche Laboratories. Ms. Markel earned a Bachelor’s degree from the University of California, Davis.

Colleen Sjogren

Chief Commercial Officer

Ms. Sjogren joined Nuvation Bio in 2024, bringing nearly 30 years of experience developing innovative, high-performing commercial organizations for successful product launches, including many leading oncology medicines.

She most recently served as the Senior Vice President of U.S. Sales at Madrigal Pharmaceuticals, where she developed the commercial sales launch plan for a first-in-class, first-to-market therapy. Previously, she was the Vice President of U.S. Sales, Sales Training, and Meeting Planning at Mirati Therapeutics, where she led the build-out of the field-facing commercial organization for the company’s first targeted oncology product launch. Prior to that role, Ms. Sjogren was the Vice President of the National Cell Therapy Team/Sales and Commercial Operations at Kite Pharma, a Gilead company, and held senior leadership roles at Medivation, Human Genome Sciences, Genentech, and Centocor. She received her B.S. and B.A. from Bryant University.

Junyuan Jerry Wang, Ph.D.

Chief Executive Officer & Co-Founder of AnHeart Therapeutics

Dr. Wang joined Nuvation Bio in 2024 as part of the acquisition of AnHeart Therapeutics. Dr. Wang serves as Chief Executive Officer of AnHeart, a Nuvation Bio company, and is a member of Nuvation Bio’s Board of Directors.

Dr. Wang co-founded AnHeart in 2018 and was appointed Chief Executive Officer. Over five years, Dr. Wang led the in-license and development of AnHeart’s two lead, potentially best-in-class, investigational medicines, taletrectinib and safusidenib. He built AnHeart into a late-stage clinical organization that gained Breakthrough Therapy Designations for taletrectinib, progressed taletrectinib into pivotal clinical trials, and progressed safusidenib into a global Phase 2 trial. AnHeart was acquired by Nuvation Bio in April 2024. 

Dr. Wang has more than 20 years of leadership experience in global clinical development and medical research across multiple therapeutic areas including oncology, cardiovascular, neuroscience, and immunology. He previously worked at Merck Serono, Bristol Myers Squibb, Wyeth/Pfizer, The Medicines Company, and Merck & Co. He made key contributions to the successful NDAs of Bosulif and Eliquis, the latter of which became a multi-billion-dollar blockbuster drug. Dr. Wang has extensive experience with global health authorities including the U.S. FDA, EMA, Japan’s PMDA, and China’s NMPA. He has served in leadership roles for professional societies, including serving on the Executive Committee of the Biopharmaceutical section of the American Statistical Association, and on the programming committee of leading scientific conferences. Dr. Wang earned his B.S. from the University of Science and Technology of China and Ph.D. in Statistics from Iowa State University.

Kerry Wentworth

Chief Regulatory Officer

Ms. Wentworth joined Nuvation Bio in 2022 with over 25 years of experience in both domestic and international Regulatory and Quality Affairs. Her background spans early and late development across multiple therapeutic areas including oncology, osteoarthritis, pain management, autoimmune and rare diseases. She also comes to Nuvation Bio with a broad scope of product knowledge ranging from injectable small molecules to complex autologous platforms.

Ms. Wentworth most recently served as Chief Regulatory Officer for Flexion Therapeutics, which was acquired by Pacira Biosciences in 2021, where she was in an executive leadership role responsible for setting and delivering on regulatory and quality strategies across their product portfolio. Most notably, Ms. Wentworth was instrumental in leading the company’s first NDA successfully through the FDA approval process and into commercialization. Prior to joining Flexion, Ms. Wentworth served as Vice President, Clinical, Regulatory and Quality at Agenus, Inc., where she was responsible for leading all global regulatory and clinical development efforts. Previously, Ms. Wentworth led the Regulatory and Quality function for Genelabs Technologies, Inc. and prior to that held positions of increasing responsibility within Regulatory Affairs at Genzyme. Ms. Wentworth holds a BS in pre-veterinary medicine from the University of New Hampshire.